QBA Meditours

Mediasten Healthcare Programs

Mediastinum is the section which seperates two lungs. Mediastinum includes heart and heart veis, thymus gland, esophagus, lymph nodes in mesothorax, cardiac nerves and trachea. Mediastinum does not include the lungs.

Mediastinal Tumor Resection: removal of the tumors in mediastinum through operation for the purpose of stopping the spreading of cancer and preventing the tumors from compressing organs in that region such as heart or lung.

Non-small Cell Lung Cancer’s Treatment

CimaVax-EGF Non-small Cell Lung Cancer Vaccination

CimaVax EGF is the product of 25 years of research program developed by Molecular Immunoloy Center and Genetic Engineerin Biotechnology Center located in Cuba. This product is the first vaccination for 3rd and 4th stage non-small cell lung cancer (NSCLC) all over the world and it is generally administered after the chemotherapy and radiotherapy. CimaVax EGF functions by targeting epidermal growth factor (EGF) (a protein naturally found in the body). In a healthy body, EGF signals for the cell division and growth by binding to superficial receptors in the cell. In some cancer types such as non-small cell lung cancer, the body generates much more EGFs and compels the cell to grow and divide in an uncontrollable wat. For the cancerous cells to grow at an extent which convinces the immune system, they should exceed the immune reaction. For a vaccination to have an impact, it should create an immune reaction which does not realize naturally. CimaVax EGF boosts the immune system and provides it to generate antibodies aiming particularly EGF and binding to it. Since EGF cannot be bond to the receptors in cancerous cells any more, growth and division signal is not taken and thus, the uncontrollable growth of cancerous cells is slowed down. CimaVax EGF does not prevent the development of cancer, however, it stimulates a mechanism which restricts the uncontrollable growth and division of cancerous cells.

CimaVax Vaccination program contains the following:

  • Initial evaluation/Issuance of Medical History Health Certificates

Diagnostic Tests:

  • CBC
  • ESR
  • Complete coaguloram Alkaline Phosphatase Blood (Serum) Glutamic -Oxaloacetic Transaminase (SGOT) Test
  • Uric Acid Test

  • Initial phase contains the delivery of 2 months of CimaVax in such a way which will correspond to 16 double vials administration (4 vials x 4 vaccination administrations). The first dose will be administered in healthcare centers located in Cuba, you can continue your treatment in Cuba or in your own country, at your own pleasure.
  • Cyclophosphamide and saline solutions.

Racotumomab (Vaxira®)
Vaccination for non-small cell lung cancer

Racotumomab (Vaxira®) vaccinations have been used for long time for activating the ability of the immune system to protect the body against foreign matters leading to infection and diseases, notably viral or bacterial, and to assist the body. The vaccination notion for the cancer treatment is arising from this fact; the immune system protects the body against viral and bacterial infections and also, it identifies the cancerous cells and protects the body from cancer by destroying such cells in most cases. Unfortunately, cancerous cells sometimes supress the immune system or hide from them and sometimes since cancerous cells are numerous, they defeat the immune system. Like the other vaccinations, the cancer vaccinations enable the immune system to recognize the different cancer types and take action against them.

Racotumomab ( Vaxira®), one of these vaccinations, prevents the tumor growth by activating the cellular and humoral immune response against NeuGc GM3 ganglioside found in some tumor tissues and slows down the development, thus, it increases the expected lifetime and life quality of the patient. Unlike traditional cancer treatments such as chemotherapy and radiotherapy where healthy cells near the cancerous cells are also damaged, racotumomab is a well-tolerated cancer treatment and its most common adverse effects are burning sensation in the arm and dull ache in the injection region and possible weakness (physical weakness or energy loss).

Racotumomab is the second non-small cell lung cancer developed following CimaVaxEGF in Cuba.